Ratings Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.574 ^USD	-1.37%		-7.52%	-23.02%

May. 15	Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 07	Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy	CI

Strengths

For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
TRAWS PHARMA, INC.	-23.02%	12.1M	-
MODERNA, INC.	+43.36%	54.63B	B-
IQVIA HOLDINGS INC.	-5.31%	39.92B	B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B	B-
CELLTRION, INC.	-12.56%	26.22B	C
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B	B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B	B+
BIO-TECHNE CORPORATION	+0.04%	12.16B	B+
MEDPACE HOLDINGS, INC.	+26.04%	11.94B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes